The recently published book, Regulation of Genome Editing in Human iPS Cells, examines two scenarios for the future treatment of hereditary diseases—either germ line therapies or somatic cell/gene therapies. Genome editing—especially by means of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins and induced pluripotent stem cells (iPSCs)—forms the essential scientific and technological components of these two therapeutic approaches.
Partner Kathy Sanzo authored the US chapter of the book, noting the United States is a “world leader in the field of cell and gene therapies,” which is “mirrored by the US regulatory framework which fosters research on, as well as development, application and marketing of, cell and gene therapy (CGT) products without compromising their safety, efficacy and quality.”
Read the Regulation of Genome Editing in Human iPS Cells: United States chapter abstract >>
Subscription may be required.